Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

The trial includes moderate to severe COVID-19. A prophylaxis can also prevent moderate from becoming severe and severe from becoming dead. The article laments the low efficacy of Remdesivir, meaning though it reduces the time for hospitalization, it doesn’t seem to sufficiently prevent a moderate case upon admission from advancing to severe before the cytokine storm finally overwhelms the virus.

The trial design will show a prophylaxis for disease progression, if B does sufficiently in clinical work what it did in lab studies.